Antiphospholipid syndrome's genetic and epigenetic aspects

Area of Science:

• Immunogenetics
• Rheumatology
• Thrombosis

Background:

• Antiphospholipid Syndrome (APS) is an autoimmune disorder associated with an increased risk of thrombosis and pregnancy complications.
• Genetic and epigenetic factors play a significant role in the development of APS.
• Previous research has identified associations with specific Human Leukocyte Antigen (HLA) alleles and inherited thrombophilia genes.

Purpose of the Study:

• To summarize the current understanding of genetic and epigenetic predispositions to Antiphospholipid Syndrome (APS).
• To highlight key genetic factors and their association with autoimmune manifestations and thrombotic events in APS.
• To discuss the emerging role of microRNAs in the pathogenesis of APS.

Main Methods:

• Review of existing literature on genetic and epigenetic factors in APS.
• Analysis of associations between specific genes (e.g., HLA, IRF5, STAT4) and APS.
• Examination of the role of inherited thrombophilia polymorphisms.
• Consideration of post-transcriptional modifications and microRNA expression patterns.

Main Results:

• Genetic predisposition to APS is strongly linked to the HLA system, particularly HLA-DR4 and HLA-DRw53.
• Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are associated with specific HLA antigens.
• Genes outside the Major Histocompatibility Complex (MHC), such as IRF5 and STAT4, and thrombophilia-related polymorphisms (Factor V Leiden, G20210A prothrombin) contribute to APS.
• Altered microRNA expression is a significant recent discovery linked to autoimmunity, thrombosis, atherosclerosis, and oxidative stress in APS.

Conclusions:

• A complex interplay of genetic and epigenetic factors underlies APS.
• Specific genetic markers and microRNA alterations are crucial in understanding APS pathogenesis.
• Further research into these factors may lead to improved diagnostics and therapeutics for APS.